Henri K.
- Country
- Estonia
- Department
- N/A
Research Overview
- Phase 3 Randomized Study Comparing Asundexian and Apixaban for Stroke Prevention in Atrial Fibrillation Patients at Risk
- HERMES: Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation
Data & Insights
Has run more than one trial at 100 of 616 partner sites.
Specializations
Cardiovascular Medicine
This investigator specializes in the field of preventive cardiology, with particular emphasis on stroke prevention in patients with cardiac conditions.
- Atrial Fibrillation Management
- Stroke Prevention Strategies
- Systemic Embolism Prevention
The research focus encompasses innovative therapeutic approaches for patients with atrial fibrillation who face elevated stroke risks.
Thrombosis Research
The investigator conducts studies in antithrombotic therapy and its applications in preventing cardiovascular events.
- Novel Anticoagulation Approaches
- Bleeding Risk Assessment
- Therapeutic Efficacy Evaluation
Their work involves assessment of new therapeutic agents for stroke prevention in cardiac conditions.
Clinical Outcomes
The investigator evaluates therapeutic effectiveness in cardiovascular medicine with a focus on patient outcomes.
- Comparative Treatment Analysis
- Safety Profile Assessment
- Risk-Benefit Evaluation
Their research examines the balance between therapeutic benefits and safety in cardiovascular treatments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.